NVO
The supply bottleneck gets a new owner
Novo Nordisk just finished its $16.5 billion takeover of Catalent, a deal that’s less about corporate wedding bells and more about getting enough factory floor to keep up with the GLP-1 gold rush. For Novo, this isn’t a vanity acquisition. It’s a practical one: more facilities, more capacity, fewer “sorry, we’re out” moments.
Why investors should care
Ozempic and Wegovy have been doing the heavy lifting for Novo, but demand has been so wild that growth keeps banging into supply constraints like a shopping cart with a busted wheel. The company says the extra manufacturing capacity should help it ramp production of its key growth medicines, which is basically code for: we think the sales story gets better if we can actually fill the prescription pipeline.
The numbers behind the frenzy
Novo says Ozempic sales climbed 26% to about $4.3 billion in the third quarter of 2024, while Wegovy sales jumped 79% to $2.5 billion. That kind of growth is why the company’s valuation has ballooned to $289 billion and why every manufacturing update gets treated like a mini earnings event.
Big picture
This deal isn’t about getting bigger for the sake of it. It’s about making sure the demand monster doesn’t outrun the supply machine. If Novo can turn more demand into shipped doses, investors get a cleaner shot at the next leg of growth.